An Information Portal to 111558 Biological Macromolecular Structures

BRL is found in 8 entries
  •   Chemical Component Summary   Hide
    Identifiers (5S)-5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
    Synonyms BRL49653
    Formula C18 H19 N3 O3 S
    Molecular Weight 357.43 g/mol
    Type non-polymer
    Isomeric SMILES
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00412   (Different stereochemistry)
    Name Rosiglitazone
    • approved
    • investigational
    Description Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be of benefit to a subset of patients with Alzheimer's disease not expressing the ApoE4 allele. This is the subject of a clinical trial currently underway.
    • (±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
    • (RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
    • Rosiglitazon
    • Rosiglitazona
    • Rosiglitazone
    • Rosiglitazonum
    Salts Rosiglitazone Maleate
    Brand names Avandia
    Affected organism Humans and other mammals
    Indication Rosiglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
    Pharmacology When rosiglitazone is used as monotherapy, it is associated with increases in total cholesterol, LDL, and HDL. It is also associated with decreases in free fatty acids. Increases in LDL occurred primarily during the first 1 to 2 months of therapy with AVANDIA and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time.
    Mechanism of action Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors regulates the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, rosiglitazone enhances tissue sensitivity to insulin.
    Route of administration oral
    ATC-Code A10BG02
    AHFS-Code 68:20.28
    CAS number 122320-73-4
    Name Sequence search Pharmacological action Actions
    Peroxisome proliferator-activated receptor gamma   Search  yes agonist
    Long-chain-fatty-acid--CoA ligase 4   Search  unknown inhibitor
Ligand Image